<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02825368</url>
  </required_header>
  <id_info>
    <org_study_id>HVT-2016</org_study_id>
    <nct_id>NCT02825368</nct_id>
  </id_info>
  <brief_title>Homeopathic Vaccine Trial</brief_title>
  <acronym>HVT</acronym>
  <official_title>Homeopathic Vaccine Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the immunological response of homeopathic vaccines to
      placebo and to conventional vaccines in healthy young adults.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody levels for diphtheria</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody levels for pertussis</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody levels for tetanus</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody levels for mumps</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody levels for measles</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Homeopathic vaccine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diphtheria (Diphtherinum®), pertussis (Pertussinum®), tetanus (Tetanotxicum®), measles (Morbilinum®) and mumps (Ourlianum®) nosodes.
Two sterile saline injections (0.5ml each, intramuscular and subcutaneous) as placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional vaccine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One intramuscular dose of Tdap (tetanus, diphtheria, acellular pertussis)
One subcutaneous dose of MMR (measles, mumps, rubella)
Sugar pellets as placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pellets oral dose
Two sterile saline injections (0.5 ml each, intramuscular and subcutaneous) as placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MMR</intervention_name>
    <description>0.5 mL, subcutaneous</description>
    <arm_group_label>Conventional vaccine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tdap</intervention_name>
    <description>0.5 mL, intramuscular</description>
    <arm_group_label>Conventional vaccine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diphtherinum®</intervention_name>
    <arm_group_label>Homeopathic vaccine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pertussinum®</intervention_name>
    <arm_group_label>Homeopathic vaccine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tetanotxicum®</intervention_name>
    <arm_group_label>Homeopathic vaccine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Morbilinum®</intervention_name>
    <arm_group_label>Homeopathic vaccine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ourlianum®</intervention_name>
    <arm_group_label>Homeopathic vaccine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sterile saline</intervention_name>
    <description>0.5 mL, intramuscular</description>
    <arm_group_label>Homeopathic vaccine group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sugar pellets</intervention_name>
    <arm_group_label>Conventional vaccine group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between the ages of 18 and 24 years

          -  Has received primary childhood DTaP and MMR vaccinations

          -  Available for a follow up visit (3 weeks after initial visit)

        Exclusion Criteria:

          -  Received a live vaccine in the past 4 weeks

          -  Has had a serious allergic reaction to a previous vaccination

          -  Has allergies to one or more of the components of the vaccines to be used (Neomycin,
             egg protein)

          -  Has a history of encephalopathy within 7 days of receiving DTP/DTap

          -  Has received nosodes for Diphtheria, Tetanus, Pertussis, Measles and Mumps

          -  Has received an adult booster dose of conventional vaccines of diphtheria, pertussis,
             tetanus, mumps, and measles (Tdap or MMR)

          -  Has received immunosuppressive doses of steroids or anti-cancer drugs in the past 3
             months

          -  Is pregnant or if there is a chance they could become pregnant during the next month

          -  Has a moderate to severe acute illness at the time of enrolment

          -  Has cancer, leukemia, HIV/AIDS, or any other serious immune health condition

          -  Has a history of Guillaume Barre Syndrome

          -  Has received blood transfusion, blood products, or immune globulin within the past
             year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mark Loeb, MD, MSc.</last_name>
    <phone>905-525-9140</phone>
    <phone_ext>26066</phone_ext>
    <email>loebm@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sasha Eskandarian, MSc</last_name>
    <phone>905-525-9140</phone>
    <phone_ext>26672</phone_ext>
    <email>eskand@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark B Loeb, MD, MSc</last_name>
      <phone>905-525-9140</phone>
      <phone_ext>26066</phone_ext>
      <email>loebm@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Sasha Eskandarian, MSc</last_name>
      <phone>905-525-9140</phone>
      <phone_ext>26672</phone_ext>
      <email>eskand@mcmaster.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Mark B Loeb, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2016</study_first_submitted>
  <study_first_submitted_qc>July 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

